<DOC>
	<DOCNO>NCT00578266</DOCNO>
	<brief_summary>For patient severe aplastic anemia ( SAA ) fail respond immunosuppressive therapy lack HLA identical family member , objective make initial assessment safety efficacy allogenic stem cell transplantation either match unrelated donor mismatch react donor use condition regimen Cytoxan , reduce total body irradiation ( TBI ) Campath IH . The principle measure safety efficacy : 1 . Patient survival probability 100 day , 1 year 2 year . 2 . Incidence graft versus host disease ( GVHD ) , well incidence acute GVHD chronic GVHD within 6 month 2 year . 3 . Engraftment 6 month , 1 year 2 year</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Patients With Severe Aplastic Anemia</brief_title>
	<detailed_description>The objective trial make initial assessment new treatment regimen show equal superior current standard practice . With initial assessment hope gain information suggest study regimen discontinuation regimen expose large number patient new treatment option . We also gain experience new regimen give insight possible modification dose monitoring selection patient future treatment case positive result . For initial study plan enroll 24 patient .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Diagnosis SAA base bone marrow aspirate biopsy result . Failure respond immunosuppressive therapy and/or lack HLA identical family member . A 10/10 9/10 HLA match unrelated donor 9/10 match related donor available high resolution type . Patients Aplastic anemia active infection must treat maximally resolve problem begin condition regimen . HIV seropositive patient Patients clonal cytogenetic abnormality myelodysplastic syndrome . Patient great 60 year age . Women pregnant nursing . Patients active hepatitis Patients severe cardiac dysfunction define shorten fraction &lt; 25 % . Patients severe renal dysfunction define creatinine clearance &lt; 40ml/mim/1.73m2 . Patient severe pulmonary dysfunction FEV1 , FVC DLCO 40 % predict 3 SD normal .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Severe Aplastic Anemia ( SAA )</keyword>
	<keyword>Transplant Severe Aplastic Anemia ( SAA )</keyword>
</DOC>